{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:44:58Z","timestamp":1794559498290,"version":"4.9.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"ENDO ERN and ERN BOND - European Reference Network for rare Bone Diseases","award":["ENDO ERN and ERN BOND - European Reference Network for rare Bone Diseases"],"award-info":[{"award-number":["ENDO ERN and ERN BOND - European Reference Network for rare Bone Diseases"]}]},{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical","doi-asserted-by":"publisher","award":["None"],"award-info":[{"award-number":["None"]}],"id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Achondroplasia is the most common form of disproportionate short stature and can lead to serious medical complications, including foramen magnum and spinal stenosis. Until 2021, there were no precision treatments available, and in some countries, elective surgery was considered a standard approach to increase height, improve body proportions, enhance functionality, and correct deformities in a selected group of patients. Recently, C-type natriuretic peptide (CNP) has been explored as a potential treatment, aiming to counteract the molecular activity driven by FGFR3. Although post-market and real-world data on the drug are still limited, many questions remain about the potential for combining pharmacological and surgical therapies and how this might influence patient outcomes. Concerns have also been raised regarding the potential impact of drugs on bone healing. However, anecdotal evidence from orthopaedic practice suggests that the two ossification processes do not interfere with one another. The aim of this study was to describe the first real-world case series in which vosoritide treatment was integrated with limb surgery in children and adolescents with achondroplasia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixteen paediatric patients with molecular confirmation of achondroplasia were included in the study. All patients underwent combined vosoritide therapy and limb surgeries (13 for lower limb lengthening and 3 for varus correction through epiphysiodesis).The complementary roles of vosoritide therapy and surgery were highlighted, with treatment outcomes aligning closely with expectations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This report provides the first clinical description of the combination of precision therapy with limb surgery in a relatively large multicentre cohort of paediatric patients with achondroplasia. These findings support continued exploration of the integration of different therapeutic approaches.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-03853-7","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T18:46:02Z","timestamp":1752777962000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Integrating vosoritide therapy with limb surgery in paediatric patients with achondroplasia: real-life experiences"],"prefix":"10.1186","volume":"20","author":[{"given":"Anna Elsa Maria","family":"Allegri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6723-9177","authenticated-orcid":false,"given":"Maria Francesca","family":"Bedeschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Beatrice","family":"Bocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Camurri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela Veronika","family":"Gonfiantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Leoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osvaldo","family":"Palmacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Porro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Riganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Tedesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berardo","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Scarano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Schiavariello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Selicorni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Stagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Verdoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Zampino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Maghnie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Onesimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"issue":"4","key":"3853_CR1","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/dvdy.24479","volume":"246","author":"DM Ornitz","year":"2017","unstructured":"Ornitz DM, Legeai-Mallet L, Achondroplasia. Development, pathogenesis, and therapy. Dev Dyn. 2017;246(4):291\u2013309.","journal-title":"Dev Dyn"},{"issue":"9582","key":"3853_CR2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S0140-6736(07)61090-3","volume":"370","author":"WA Horton","year":"2007","unstructured":"Horton WA, Hall JG, Hecht JT. Achondroplasia Lancet. 2007;370(9582):162\u201372.","journal-title":"Achondroplasia Lancet"},{"issue":"10","key":"3853_CR3","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1002\/ajmg.a.61787","volume":"182","author":"PK Foreman","year":"2020","unstructured":"Foreman PK, van Kessel F, van Hoorn R, van den Bosch J, Shediac R, Landis S. Birth prevalence of achondroplasia: A systematic literature review and meta-analysis. Am J Med Genet A. 2020;182(10):2297\u2013316.","journal-title":"Am J Med Genet A"},{"key":"3853_CR4","doi-asserted-by":"crossref","unstructured":"Rintz E, Wegrzyn G, Fujii T, Tomatsu S. Molecular mechanism of induction of bone growth by the C-Type natriuretic peptide. Int J Mol Sci. 2022;23(11).","DOI":"10.3390\/ijms23115916"},{"issue":"17","key":"3853_CR5","first-page":"2057","volume":"81","author":"S Duggan","year":"2021","unstructured":"Duggan S, Vosoritide. First Approval Drugs. 2021;81(17):2057\u201362.","journal-title":"First Approval Drugs"},{"issue":"1","key":"3853_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1056\/NEJMoa1813446","volume":"381","author":"R Savarirayan","year":"2019","unstructured":"Savarirayan R, Irving M, Bacino CA, Bostwick B, Charrow J, Cormier-Daire V, et al. C-Type natriuretic peptide analogue therapy in children with achondroplasia. N Engl J Med. 2019;381(1):25\u201335.","journal-title":"N Engl J Med"},{"issue":"10252","key":"3853_CR7","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/S0140-6736(20)31541-5","volume":"396","author":"R Savarirayan","year":"2020","unstructured":"Savarirayan R, Tofts L, Irving M, Wilcox W, Bacino CA, Hoover-Fong J, et al. Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial. Lancet. 2020;396(10252):684\u201392.","journal-title":"Lancet"},{"issue":"12","key":"3853_CR8","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1038\/s41436-021-01287-7","volume":"23","author":"R Savarirayan","year":"2021","unstructured":"Savarirayan R, Tofts L, Irving M, Wilcox WR, Bacino CA, Hoover-Fong J, et al. Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study. Genet Med. 2021;23(12):2443\u20137.","journal-title":"Genet Med"},{"key":"3853_CR9","doi-asserted-by":"crossref","unstructured":"Paley D. Extensive limb lengthening for achondroplasia and hypochondroplasia. Child (Basel). 2021;8(7).","DOI":"10.3390\/children8070540"},{"issue":"1","key":"3853_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s10195-019-0541-3","volume":"21","author":"GA Hosny","year":"2020","unstructured":"Hosny GA. Limb lengthening history, evolution, complications and current concepts. J Orthop Traumatol. 2020;21(1):3.","journal-title":"J Orthop Traumatol"},{"key":"3853_CR11","doi-asserted-by":"publisher","first-page":"1209994","DOI":"10.3389\/fped.2023.1209994","volume":"11","author":"M Maghnie","year":"2023","unstructured":"Maghnie M, Bruzzi P, Casilli G, Lidonnici D, Scarano G. The management of achondroplasia in italy: results from a Delphi panel based on real-world experience. Front Pediatr. 2023;11:1209994.","journal-title":"Front Pediatr"},{"issue":"3","key":"3853_CR12","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41574-021-00595-x","volume":"18","author":"R Savarirayan","year":"2022","unstructured":"Savarirayan R, Ireland P, Irving M, Thompson D, Alves I, Baratela WAR, et al. International consensus statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia. Nat Rev Endocrinol. 2022;18(3):173\u201389.","journal-title":"Nat Rev Endocrinol"},{"key":"3853_CR13","doi-asserted-by":"crossref","unstructured":"Fernandes JA, Devalia KL, Moras P, Pagdin J, Jones S, McMullan J. Screening for spinal stenosis in achondroplastic patients undergoing limb lengthening. J Pediatr Orthop B. 2014;23(2).","DOI":"10.1097\/BPB.0000000000000027"},{"issue":"10","key":"3853_CR14","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1111\/head.12246","volume":"53","author":"JJ Gagnier","year":"2013","unstructured":"Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D, et al. The CARE guidelines: consensus-based clinical case reporting guideline development. Headache. 2013;53(10):1541\u20137.","journal-title":"Headache"},{"key":"3853_CR15","doi-asserted-by":"crossref","unstructured":"Hoover-Fong J, Scott CI, Jones MC, Committee On G. Health supervision for people with achondroplasia. Pediatrics. 2020;145(6).","DOI":"10.1542\/peds.2020-1010"},{"issue":"2","key":"3853_CR16","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s40618-023-02151-y","volume":"47","author":"MF Bedeschi","year":"2024","unstructured":"Bedeschi MF, Mora S, Antoniazzi F, Boero S, Ravasio R, Scarano G, et al. The clinical management of children with achondroplasia in italy: results of clinician and parent\/caregiver surveys. J Endocrinol Invest. 2024;47(2):345\u201356.","journal-title":"J Endocrinol Invest"},{"issue":"16","key":"3853_CR17","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.2106\/JBJS.21.00584","volume":"103","author":"AG Georgiadis","year":"2021","unstructured":"Georgiadis AG, Morrison SG, Dahl MT. What\u2019s new in limb lengthening and deformity correction. J Bone Joint Surg Am. 2021;103(16):1467\u201372.","journal-title":"J Bone Joint Surg Am"},{"issue":"Suppl 2","key":"3853_CR18","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/BPO.0000000000001021","volume":"37","author":"JG Birch","year":"2017","unstructured":"Birch JG. A brief history of limb lengthening. J Pediatr Orthop. 2017;37(Suppl 2):S1\u20138.","journal-title":"J Pediatr Orthop"},{"key":"3853_CR19","unstructured":"Voxzogo - Summary. of Product Characteristics [Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/voxzogo-epar-product-information_en.pdf"},{"key":"3853_CR20","unstructured":"Voxzogo - Riassunto. delle caratteristiche del prodotto [Available from: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2021\/20210826152503\/anx_152503_it.pdf"},{"key":"3853_CR21","unstructured":"Achondroplasia Growth Charts For. growth monitoring of patients with achondroplasia [Available from: https:\/\/www.achondroplasia-growthcharts.com\/"},{"issue":"8","key":"3853_CR22","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1002\/ajmg.a.38853","volume":"176","author":"A Merker","year":"2018","unstructured":"Merker A, Neumeyer L, Hertel NT, Grigelioniene G, Makitie O, Mohnike K, et al. Growth in achondroplasia: development of height, weight, head circumference, and body mass index in a European cohort. Am J Med Genet A. 2018;176(8):1723\u201334.","journal-title":"Am J Med Genet A"},{"issue":"1","key":"3853_CR23","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s13023-022-02374-x","volume":"17","author":"M Pesl","year":"2022","unstructured":"Pesl M, Verescakova H, Skutkova L, Strenkova J, Krejci P. A registry of achondroplasia: a 6-year experience from the Czechia and Slovak Republic. Orphanet J Rare Dis. 2022;17(1):229.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3853_CR24","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s13023-024-03236-4","volume":"19","author":"S Boero","year":"2024","unstructured":"Boero S, Vodopiutz J, Maghnie M, de Bergua JM, Ginebreda I, Kitoh H, et al. International expert opinion on the considerations for combining vosoritide and limb surgery: a modified Delphi study. Orphanet J Rare Dis. 2024;19(1):347.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3853_CR25","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1186\/s13023-021-01971-6","volume":"16","author":"V Cormier-Daire","year":"2021","unstructured":"Cormier-Daire V, AlSayed M, Ben-Omran T, de Sousa SB, Boero S, Fredwall SO, et al. The first European consensus on principles of management for achondroplasia. Orphanet J Rare Dis. 2021;16(1):333.","journal-title":"Orphanet J Rare Dis"},{"key":"3853_CR26","doi-asserted-by":"publisher","first-page":"115320","DOI":"10.1016\/j.bone.2020.115320","volume":"135","author":"JW Robinson","year":"2020","unstructured":"Robinson JW, Blixt NC, Norton A, Mansky KC, Ye Z, Aparicio C, et al. Male mice with elevated C-type natriuretic peptide-dependent Guanylyl cyclase-B activity have increased osteoblasts, bone mass and bone strength. Bone. 2020;135:115320.","journal-title":"Bone"},{"issue":"2","key":"3853_CR27","doi-asserted-by":"publisher","first-page":"109380","DOI":"10.1016\/j.celrep.2021.109380","volume":"36","author":"H Watanabe-Takano","year":"2021","unstructured":"Watanabe-Takano H, Ochi H, Chiba A, Matsuo A, Kanai Y, Fukuhara S, et al. Mechanical load regulates bone growth via periosteal osteocrin. Cell Rep. 2021;36(2):109380.","journal-title":"Cell Rep"},{"issue":"1","key":"3853_CR28","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13023-023-02652-2","volume":"18","author":"M Maghnie","year":"2023","unstructured":"Maghnie M, Semler O, Guillen-Navarro E, Selicorni A, Heath KE, Haeusler G, et al. Lifetime impact of achondroplasia study in Europe (LIAISE): findings from a multinational observational study. Orphanet J Rare Dis. 2023;18(1):56.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3853_CR29","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s12325-023-02705-9","volume":"41","author":"O Semler","year":"2024","unstructured":"Semler O, Cormier-Daire V, Lausch E, Bober MB, Carroll R, Sousa SB, et al. Vosoritide therapy in children with achondroplasia: early experience and practical considerations for clinical practice. Adv Ther. 2024;41(1):198\u2013214.","journal-title":"Adv Ther"},{"key":"3853_CR30","doi-asserted-by":"crossref","unstructured":"Hoover-Fong J, Irving M, Bacino C, Charrow J, Prada C, Cormier-Daire V et al. P144: persistence of growth-promoting effects in children with achondroplasia up to 7 years: update from phase 2 extension study with vosoritide*. Genet Med Open. 2024;2.","DOI":"10.1016\/j.gimo.2024.101041"},{"key":"3853_CR31","unstructured":"VOXZOGO (vosoritide.) - Valutazione dell\u2019innovativit\u00e0 [Available from: https:\/\/www.aifa.gov.it\/documents\/20142\/1764848\/67_VOXZOGO_scheda_innovativita_GRADE.pdf"},{"issue":"6","key":"3853_CR32","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s11832-016-0780-2","volume":"10","author":"I Hvid","year":"2016","unstructured":"Hvid I, Horn J, Huhnstock S, Steen H. The biology of bone lengthening. J Child Orthop. 2016;10(6):487\u201392.","journal-title":"J Child Orthop"},{"key":"3853_CR33","doi-asserted-by":"publisher","first-page":"117268","DOI":"10.1016\/j.bone.2024.117268","volume":"190","author":"MS Cheung","year":"2024","unstructured":"Cheung MS, Alves I, Carl-Innig P, Eastwood D, Maghnie M, Offiah A, et al. Meeting report from the 3rd ISCBH-ERN BOND achondroplasia workshop on long bone pathology in children with achondroplasia, salzburg, Austria 22nd June 2024. Bone. 2024;190:117268.","journal-title":"Bone"},{"key":"3853_CR34","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/1752-1947-2-263","volume":"2","author":"A Al Kaissi","year":"2008","unstructured":"Al Kaissi A, Ganger R, Klaushofer K, Rumpler M, Grill F. Achondroplasia manifesting as enchondromatosis and ossification of the spinal ligaments: a case report. J Med Case Rep. 2008;2:263.","journal-title":"J Med Case Rep"},{"issue":"Suppl 1","key":"3853_CR35","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1007\/s00256-006-0161-x","volume":"36","author":"C Numakura","year":"2007","unstructured":"Numakura C, Kobayashi H, Hasegawa Y, Adachi M, Kim OH, Nishimura G. Achondroplasia and enchondromatosis: report of three boys. Skeletal Radiol. 2007;36(Suppl 1):S29\u201333.","journal-title":"Skeletal Radiol"},{"issue":"11","key":"3853_CR36","doi-asserted-by":"publisher","first-page":"104850","DOI":"10.1016\/j.ejmg.2023.104850","volume":"66","author":"R Onesimo","year":"2023","unstructured":"Onesimo R, Sforza E, Bedeschi MF, Leoni C, Giorgio V, Rigante D, et al. How pain affect real life of children and adults with achondroplasia: A systematic review. Eur J Med Genet. 2023;66(11):104850.","journal-title":"Eur J Med Genet"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03853-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03853-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03853-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T13:34:55Z","timestamp":1757252095000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03853-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3853"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03853-7","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,17]]},"assertion":[{"value":"28 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The local ethics committee approved the use of vosoritide. Owing to its retrospective nature, no ethics committee approval was necessary for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent for publication was obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AEM Allegri declares the following conflict of interest: lecture and advisory board fees: BioMarin; financial support for training conferences: BioMarin, Pfizer and Sandoz. MF Bedeschi has received funding as a principal investigator for Sanofi, Biomarin, and QED clinical trials and from Biomarin as speaker in sponsored symposia and from Biomarin as a member of the Advisory Board. M. V. Gonfiantini has received funding as a principal investigator for Amgen and Biomarin clinical trials and for participating in advisory boards on Achondroplasia for Biomarin. M Maghnie received Grant support from Pfizer, Novo Nordisk and Merck Serono and consultancy. honoraria and speaker fees from Pfizer, Merck Serono, Novo Nordisk, Sandoz, and BioMarin. M Mariani declares the following conflicts of interest: Biomarin, Pfizer. R Onesimo received funding as the principal investigator for Sanofi, Biomarin, and QED clinical trials from Biomarin as speaker in sponsored symposia and from Biomarin as a member of the advisory board. B Rinaldi declares the following conflicts of interest: Biomarin, Sanofi, and QED clinical trials. A Selicorni declares the following conflicts of interest: Biomarin, Pfizer. G Zampino has received funding as a principal investigator for Pfizer clinical trials. MB Bocchi, V. Camurri, C. Leoni, O. Palmacci, M. Porro, S. Riganti, E. Scarano, and C. Schiavarello have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"369"}}